(Total Views: 144)
Posted On: 10/20/2020 11:09:25 AM
Post# of 38741
$NBIO October 20, 2020 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech" or the "Company"
is pleased to announce that the Company has received initial In-Vitro study results from its collaboration with Syracuse University showing that Pritumumab ("PTB" successfully blocked viral entry into cells. Based on these results, PTB and will be advanced to laboratory-based animal studies. https://www.otcmarkets.com/stock/NBIO/news/st...id=1718701
is pleased to announce that the Company has received initial In-Vitro study results from its collaboration with Syracuse University showing that Pritumumab ("PTB" successfully blocked viral entry into cells. Based on these results, PTB and will be advanced to laboratory-based animal studies. https://www.otcmarkets.com/stock/NBIO/news/st...id=1718701
(0)
(0)
